--- title: "Unicycive Therapeutics Metrics Guide" description: "Unicycive Therapeutics Inc. revenue, margins, cash flow and balance sheet figures by fiscal year, taken from its SEC filings, with the ratios explained." canonical: https://www.getswoopr.com/stocks/companies/unicycive-therapeutics-inc/financial-metrics/ source: "Swoopr Investment: https://www.getswoopr.com" --- # Unicycive Therapeutics Inc. Financial Metrics Guide ## Direct Answer > Unicycive Therapeutics Inc. reported revenue of $675,000 for the fiscal year ended December 31, 2023, with an operating margin of -3077.6% and net income of -$31 million, according to its SEC filings. Revenue fell 29.0% from the prior year. ## What Are Unicycive Therapeutics Inc.'s Key Financial Figures? | Fiscal year | FY2023ended December 31, 2023 | FY2022ended December 31, 2022 | | --- | --- | --- | | Revenue | $675,000 | $951,000 | | Operating income | -$21 million | -$18 million | | Operating margin | -3077.6% | -1898.2% | | Net income | -$31 million | -$18 million | | Net margin | -4525.0% | -1898.8% | | Operating cash flow | -$18 million | -$16 million | | Capital expenditures | $12,000 | $2,000 | | Free cash flow | -$18 million | -$16 million | Operating margin narrowed by 1179.4 percentage points between fiscal 2022 and 2023, which separates pricing and cost discipline from revenue growth alone. Free cash flow (operating cash flow minus capital expenditures) was -$18 million against net income of -$31 million; cash generation covered reported earnings. ![Bar chart of Unicycive Therapeutics Inc. revenue, operating income, net income for fiscal 2022 to 2023. In fiscal 2023, revenue was $675,000, operating income negative $21 million and net income negative $31 million.](https://www.getswoopr.com/images/charts/unicycive-therapeutics-inc-metrics-revenue-profit.webp) *Unicycive Therapeutics Inc. revenue, operating income and net income by fiscal year, from the figures in the table above. Select the chart to open it full size.* ![Line chart of Unicycive Therapeutics Inc. operating margin and net margin for fiscal 2022 to 2023. In fiscal 2023, operating margin was -3077.6% and net margin was -4525.0%.](https://www.getswoopr.com/images/charts/unicycive-therapeutics-inc-metrics-margins.webp) *Unicycive Therapeutics Inc. operating margin and net margin by fiscal year: operating income and net income as a share of revenue. Select the chart to open it full size.* ![Bar chart of Unicycive Therapeutics Inc. operating cash flow, capital expenditures, free cash flow for fiscal 2022 to 2023. In fiscal 2023, operating cash flow was negative $18 million, capital expenditures was $12,000, free cash flow was negative $18 million.](https://www.getswoopr.com/images/charts/unicycive-therapeutics-inc-metrics-cash-flow.webp) *Unicycive Therapeutics Inc. operating cash flow, capital expenditures and free cash flow by fiscal year. Select the chart to open it full size.* ## What Does Unicycive Therapeutics Inc.'s Balance Sheet Show? | Cash and cash equivalents | $10 million | | --- | --- | | Long-term debt | Not reported | | Total assets | $14 million | | Total liabilities | $18 million | | Shareholders' equity | -$4 million | | Current ratio | 0.8x | Balance sheet values are as of the end of fiscal 2023. Income statement figures describe a whole year; balance sheet figures describe a single day, so the two answer different questions. ## Where These Numbers Come From Every figure on this page is a value Unicycive Therapeutics Inc. reported in its own SEC filings, read from the SEC's XBRL data (accession 0001213900-25-025828 for fiscal year 2023). Ratios are computed from those reported values. Figures were retrieved on October 7, 2026; a later amendment or a new annual report can change them, and the filing itself always takes precedence over this summary. Each fiscal year is labeled by the calendar year in which it ended, so a company that names the same period differently in its own filings (many retailers whose year ends in January) may use another label. A year is left out of the table when the SEC data set holds no value for it. A figure shown as "Not reported" means the company did not file a value under the standard tag Swoopr reads, not that the amount was zero. This page is educational and describes reported history only; it is not a forecast or a recommendation. ## Frequently Asked Questions ### What was Unicycive Therapeutics Inc.'s revenue in fiscal 2023? Unicycive Therapeutics Inc. reported revenue of $675,000 for the fiscal year ended December 31, 2023, according to its SEC filings. ### What is Unicycive Therapeutics Inc.'s operating margin? Unicycive Therapeutics Inc.'s operating margin was -3077.6% in fiscal 2023: operating income of -$21 million on revenue of $675,000. ### How much free cash flow did Unicycive Therapeutics Inc. generate? Operating cash flow of -$18 million less capital expenditures of $12,000 gives free cash flow of -$18 million for fiscal 2023. ## References - [SEC EDGAR: Unicycive Therapeutics, Inc. Form 10-K filed March 30, 2026](https://www.sec.gov/Archives/edgar/data/1766140/000121390026035903/ea0281982-10k_unicycive.htm) - [SEC EDGAR: Unicycive Therapeutics, Inc. annual and quarterly filings](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1766140&type=10-K) - [SEC: EDGAR application programming interfaces (XBRL frames and submissions data)](https://www.sec.gov/search-filings/edgar-application-programming-interfaces) ## Related Pages - [Unicycive Therapeutics Inc. company dossier](https://www.getswoopr.com/stocks/companies/unicycive-therapeutics-inc/) - [Unicycive Therapeutics Inc. financial metrics](https://www.getswoopr.com/stocks/companies/unicycive-therapeutics-inc/financial-metrics/) - [Unicycive Therapeutics Inc. financial risk indicators](https://www.getswoopr.com/stocks/companies/unicycive-therapeutics-inc/risks-monitoring/) - [Unicycive Therapeutics Inc. business model and revenue mix](https://www.getswoopr.com/stocks/companies/unicycive-therapeutics-inc/business-model/) - [Fundamental analysis guides](https://www.getswoopr.com/learn/fundamental-analysis/) [Swoopr Editorial Team](https://www.getswoopr.com/authors/swoopr-editorial-team/) Swoopr's editorial team produces independent investment education content. Content is for educational purposes only and does not constitute personalized investment advice. See our [editorial policy](https://www.getswoopr.com/legal/editorial-policy/) and [corrections policy](https://www.getswoopr.com/legal/corrections-policy/).